Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeNeDuctus Trial
NCT02884219Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2016
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ibuprofen in patent ductus arteriosus (PDA) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Composite of mortality, and/or necrotizing enterocolitis (NEC), and/or bronchopulmonary dysplasia (BPD). Started Dec 2016; status: completed.
02
Drugs
ibuprofen
03
Conditions
patent ductus arteriosus (PDA)
Beyond the preview
Go deeper on NCT02884219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02884219.